GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission
July 28 2021 - 7:18AM
Dow Jones News
By Chris Wack
GlaxoSmithKline PLC and Vir Biotechnology Inc. said they have
signed a joint procurement agreement with the European Commission
to supply up to 220,000 doses of Covid-19 treatment sotrovimab.
The companies said sotrovimab is an investigational single-dose
SARS-CoV-2 monoclonal antibody for the treatment of adults and
adolescents with Covid-19 who don't require oxygen supplementation
and who are at risk of progressing to severe Covid-19.
The agreement enables participating European Union member states
to quickly purchase sotrovimab, following local emergency
authorization or authorization at the EU level, to treat high-risk
patients with Covid-19 who may benefit from early treatment with
the medication, the companies said.
Sotrovimab is included in the European Commission's portfolio of
promising candidate therapies as part of its Covid-19 Therapeutics
Strategy.
Glaxo and Vir have secured supply agreements with a number of
governments around the world and will continue those efforts as the
pandemic continues to evolve, the companies said. In May,
sotrovimab was granted emergency-use authorization by the U.S. Food
and Drug Administration for the treatment of mild-to-moderate
Covid-19 in high-risk patients. Glaxo and Vir plan to submit a
biologics license application to the U.S. FDA in the second half of
2021.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 28, 2021 07:05 ET (11:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
